Trulieve Cannabis (TRLV) EBITDA (2020 - 2026)

Trulieve Cannabis has reported EBITDA for 7 years, with the latest figure at -$370.5 million in Q2 2026.

• On a quarterly basis, EBITDA fell 803.96% year-over-year to -$370.5 million in Q2 2026; TTM through Jun 2026 was -$277.3 million, a 415.48% decrease from a year earlier, with the FY2025 full-year figure at $196.6 million, up 31.74% from the prior year.
• EBITDA was -$370.5 million for Q2 2026 at Trulieve Cannabis, down from $35.7 million in the prior quarter.
• The five-year high for EBITDA was $61.6 million in Q2 2022, with the low at -$370.5 million in Q2 2026.
• Average EBITDA over 5 years is -$7.2 million, with a median of $36.7 million recorded in 2023.
• The sharpest annual moves came in 2025 and 2026: EBITDA soared 6734.63% in 2025, then sank 803.96% in 2026.
• Over 5 years, EBITDA stood at $30.0 million in 2022, then surged by 56.65% to $47.0 million in 2023, then slumped by 97.22% to $1.3 million in 2024, then jumped by 1069.5% to $15.3 million in 2025, then slumped by 2522.19% to -$370.5 million in 2026.
• The last three EBITDA figures came in at -$370.5 million (Q2 2026), $35.7 million (Q1 2026), and $15.3 million (Q4 2025), per Business Quant data.